$15.00
Market Cap
$1.03B
Shares Outstanding
64.4M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Sep 29, 2023
Round Lot
100
Locale
US
Day Open
$15.92
Day High
$16.19
Day Low
$14.87
Volume
171.3K
VWAP
$15.41
Prev Close
$15.93
Transactions
--
Acc. Volume
--
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Adlai Nortye Group Ltd. American Depositary Shares (ANL) closed the 2026-09-15 session at $15.00, down 5.84% versus the previous close (-0.93). The stock opened at $15.92 and traded between $14.87 and $16.19 during that session. Session trading volume was 171K shares. The volume-weighted average price (VWAP) is $15.41.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Adlai Nortye Group Ltd. American Depositary Shares has a market capitalization of $1.03 billion. ANL is listed on the XNAS exchange. The company employs approximately 109 people. The recorded listing date is 2023-09-29.
On this page you can find market ANL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.